Luminespib (
INN, previously known as NVP-AUY922) is an experimental drug candidate for the treatment of cancer. It was discovered through a collaboration between The
Institute of Cancer Research
The Institute of Cancer Research (the ICR) is a public research institute and a member institution of the University of London in London, United Kingdom, specialising in oncology. It was founded in 1909 as a research department of the Royal Mar ...
and the pharmaceutical company
Vernalis and licensed to
Novartis. From 2011 to 2014 it was in Phase II clinical trials.
Chemically it is a
resorcinylic isoxazole amide
[
Luminespib is an ]inhibitor
Inhibitor or inhibition may refer to:
In biology
* Enzyme inhibitor, a substance that binds to an enzyme and decreases the enzyme's activity
* Reuptake inhibitor, a substance that increases neurotransmission by blocking the reuptake of a neurotra ...
of heat shock protein 90 (Hsp90),[ which is a chaperone protein that plays a role in the modification of a variety of proteins that have been implicated in oncogenesis. Luminespib has shown promising activity in preclinical testing against several different tumor types.][
]
See also
* Hsp90 inhibitor
An Hsp90 inhibitor is a substance that inhibits that activity of the Hsp90 heat shock protein. Since Hsp90 stabilizes a variety of proteins required for survival of cancer cells, these substances may have therapeutic benefit in the treatment of va ...
s
References
Carboxamides
Experimental cancer drugs
Isoxazoles
Morpholines
Resorcinols
{{antineoplastic-drug-stub